NEW YORK (360Dx) – Oxford Immunotec reported after the close of the market on Monday that its fourth quarter revenues rose 22 percent year over year as product revenues spiked due in part to a new sales agreement with Quest Diagnostics.

For the three months ended Dec. 31, 2018, the Oxford, UK-based company tallied $15.4 million in total revenues compared to $12.6 million a year ago and edging analysts' consensus estimate of $15.1 million in revenues.